BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer (NCT06756932)
A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-21447 (a Bcl-2 Inhibitor) Combinations for Patients With HR+/HER2- Metastatic Breast Cancer
🩺 Plain-English Summary (8th-Grade Level)
This is a dose escalation and dose expansion study to assess the safety and tolerability of BGB-21447 (a B-cell leukemia/lymphoma 2 inhibitor, Bcl-2i) in combination with fulvestrant, with or without BGB-43395 (cyclin-dependent kinase 4 inhibitor, CDK4i), in adults with HR+/HER2- metastatic breast cancer.
Who can join: Review the eligibility criteria below.
Location: University of Iowa Hospitals and Clinics — Iowa City, Iowa
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (14 Sites)
- University of Iowa Hospitals and Clinics — Iowa City, Iowa
- Md Anderson Cancer Center — Houston, Texas
- Fred Hutchinson Cancer Research Center — Seattle, Washington
- Saint Vincents Hospital Sydney — Darlinghurst, New South Wales
- Calvary Mater Newcastle — Waratah, New South Wales
- Sunshine Coast University Private Hospital — Birtinya, Queensland
- Peter Maccallum Cancer Centre — Melbourne, Victoria
- Western Health Sunshine Hospital — St Albans, Victoria
- Linear Clinical Research — Nedlands, Western Australia
- Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South) — Guangzhou, Guangdong
- The First Affiliated Hospital of Zhengzhou University — Zhengzhou, Henan
- Fudan University Shanghai Cancer Centerpudong — Shanghai, Shanghai Municipality
- Tianjin Medical University Cancer Institute and Hospital — Tianjin, Tianjin Municipality
- Sir Run Run Shaw Hospital, Zhejiang University School of Medicine — Hangzhou, Zhejiang
📞 Contact the Study Coordinator
Phone: (877) 828-5568
Email: clinicaltrials@beonemed.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Hormone-receptor-positive Breast Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.